Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive

详细信息	查看全文 | 推荐本文 |

• 作者：Karen E. Elkind-Hirsch ; Carmen Darensbourg ; Beverly Ogden ; Lauren F. Ogden ; Philip Hindelang
• 关键词：Metabolic change ; Vaginal hormonal contraception ; Insulin sensitivity ; Oral contraceptive
• 刊名：Contraception
• 出版年：2007
• 期刊代码：71_00107824
• 类别：med
• 出版时间：November 2007
• 卷：76
• 期：5
• 页码：348-356
• 文件大小：320 K

摘要

This study compared metabolic, hormonal and lipid profiles before and during use of a contraceptive vaginal ring (RING) releasing 15 mcg ethinyl estradiol (EE) and 120 mcg etonogestrel per day (NuvaRing®, Organon USA Inc., Roseland, NJ) versus a low-dose oral contraceptive (PILL) containing 20 mcg EE and 100 mcg levonorgestrel daily (Aviane, Barr Pharmaceuticals Inc., Pomona, NY).

Study Design

Sixty-five women were randomized to either the RING or PILL treatment for five cycles. In the pretreatment cycle (Cycle Days 2–5) and during Weeks 2 and 3 of the fifth treatment cycle, a 75-g oral glucose tolerance test (OGTT) was performed. Baseline samples were used to evaluate basal hormonal, metabolic and lipid levels.

Results

Forty-two women completed the study. Basal insulin resistance (HOMA-IR) was slightly decreased, whereas a significant reduction in the insulin sensitivity index (IS_OGTT) was found in women on PILL therapy compared to those in the RING group (p<.035). Pancreatic β-cell function was not significantly altered with either treatment.

Conclusion

The lower-dose, nonoral hormonal RING had a lesser impact on carbohydrate metabolism and greater reduction of free androgen and dehydroepiandrosterone sulfate levels than PILL treatment.